NGAL News

NGAL Workshop – Why All the Hype?

Alpha Laboratories’ Industry Sponsored Workshop at the ACB FOCUS 2013 Meeting in York last month attracted over 50 participants. The event was reviewed by Dr Ruth Ayling – Consultant Biochemist, Derriford Hospital, Plymouth: This workshop brought together Dr Andreas Peter from the Division of Endocrinology and Metabolism, University of Tubingen, Germany and Professor Roy Sherwood from

Continue Reading

NGAL in Sepsis

Severe sepsis is a major cause of mortality and morbidity, with a mortality rate of 35%. Claiming between 36000 and 64000 lives annually in the UK, more people die from sepsis than lung cancer and more than from breast cancer and bowel cancer combined. Research shows that early recognition and intervention saves lives and could

Continue Reading

15-50% Cardiac Surgery Patients Develop AKI

Acute Kidney Injury (AKI) following cardiac surgery is a significant cause of death worldwide. Xin et al1 stated that about 15-50% of cardiac surgery patients will develop AKI. In order to optimise renal function in a focused and effective way, it is important that the clinician knows if the patient has AKI at an early

Continue Reading

Save the NHS £158 million

The National Clinical Director for kidney care Dr O’Donoghue has stated: Acute Kidney Injury is common and harmful. It is also treatable and avoidable”. Acute kidney injury also costs our NHS a lot of money, about half a billion a year, in fact.1

Continue Reading

Fastest in the World?

Usain Bolt may be the fastest man on earth, but NGAL is the fastest marker for Acute Kidney Injury (AKI). Neutrophil Gelatinase-associated Lipocalin (NGAL) is also one of the most sensitive markers for AKI. It changes the diagnosis and management of Acute Kidney Injury by detecting and predicting acute renal failure within 2-3 hours after

Continue Reading

About the NGAL Assay

Although NGAL is best known as being a biomarker of acute kidney injury (AKI), and is proving to be of great value in drug development in this context, it is now being implicated in as a key component of a number of other pathways and disease states. These include cancer, inflammation and sepsis.

Our sensitive and reliable ELISA based NGAL assays provide a reliable and sensitive means of measuring NGAL levels in both pharmaceutical and medical research settings.

Read More